Effects of duloxetine on pain and walking distance in neuropathic pain models via modulation of the spinal monoamine system

Minami, Kazuhiko; Tamano, Ryuta; Kasai, Erika; Ōyama, Hiroshi; Hasegawa, Minoru; Shinohara, Shunji; Asaki, Toshiyuki

doi:10.1002/ejp.1125

Cited by 13 publications

(9 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25 Atf-3 mRNA in DRG neurons was found to increase after nerve damage. 26 This indicated that Atf3 may be a candidate genetic marker in the progression of NP. Additionally, chemokines, by binding to Gpr151, play important roles in pathological pain states activated by either peripheral nerve injury or inflammation.…”

Section: Discussionmentioning

confidence: 98%

Identification of key candidate genes in neuropathic pain by integrated bioinformatic analysis

Tang

Jing

Huang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

This study aimed to disclose differentially expressed genes (DEGs) in dorsal root ganglia (DRGs) of neuropathic pain (NP) from spared nerve injury (SNI) model, thereby identifying specific and meaningful genetic targets for the diagnosis and treatment of NP. The GSE89224 was downloaded from the GEO database. DEGs were screened using the GEO2R online tool. Functional enrichment analysis of DEGs was then performed using the DAVID and constructed using the R ggplot2 package. Protein‐protein interaction (PPI) network was constructed from the STRING database and visualized in Cytoscape software. MicroRNA targeting these DEGs was obtained from the TarBase and miRTarBase database, while transcription factor (TF)‐targeting DEGs were predicted from the ENCODE database, both of which utilized the visual analytics platform NetworkAnayst. Finally, a merged microRNA‐TF network was constructed based on the above two networks and was then analyzed with Cytoscape. Eighty DEGs were screened, only Vstm2b and Htr3a were downregulated and 78 genes were upregulated. The real‐time polymerase chain reaction was applied to validate the gene expression of the top five DEGs (Npy, Atf3, Gpr151, Sprr1a, and Cckbr) in the DRG tissue 5 days after SNI surgery. It was found that Npy, Atf3, and Sprr1a have a significant increase after SNI stimulation, while Gpr151 and Cckbr showed a slight upward trend. Functional analysis was performed on all DEGs, of which 58 biological processes were enriched by gene ontology analysis, and 11 signaling pathways were enriched by KEGG analysis. In the PPI network, Atf3, Jun, Timp, and Npy had a higher degree. Thus, combined with various bioinformatic analyses, Npy and Atf3 may serve as the prognostic and therapeutic targets of NP. Key microRNA (mmu‐mir‐16‐5p) and TF (MEF2A) were predicted to be associated with the pathogenetic process of NP with microRNA‐TF regulatory network analysis, which were also identified as key regulators in the progression of NP.

show abstract

Section: Discussionmentioning

confidence: 98%

Identification of key candidate genes in neuropathic pain by integrated bioinformatic analysis

Tang

Jing

Huang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…to be due to activation of the descending inhibitory pain pathway, which leads to normalization of the dysfunctional process, a finding that is supported in rat neuropathic pain models 21,22) . The observed reduction in pain intensity might be partially explained by the duloxetineinduced analgesic effect, independent of its antidepressant and anxiolytic effects.…”

Section: Discussionmentioning

confidence: 75%

Reduction in anxiety during treatment with exercise and duloxetine is related to improvement of low back pain-related disability in patients with non-specific chronic low back pain

Onda

Kimura

2020

FJMS

View full text Add to dashboard Cite

“…In an animal study, the analgesic effects of pregabalin were weaker in the cauda equina compression model without an improvement in the walking distance than in the partial sciatic nerve ligation model; the expression of α 2 δ-1 subunit significantly increased only in the partial sciatic nerve ligation model and remained unchanged in the cauda equina compression model. However, duloxetine had analgesic effects in both models and improved walking distance in the cauda equina compression model 40 . The expression of the α 2 δ-1 subunit may be specific to the injury type.…”

Section: Discussionmentioning

confidence: 89%

Symptom-based pharmacotherapy for neuropathic pain related to spinal disorders: results from a patient-based assessment

Nakajima

Watanabe

Honjoh

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Existing guidelines advocate an updated therapeutic algorithm for chronic neuropathic pain (NeP), but pharmacotherapeutic management should be individualized to pain phenotypes to achieve higher efficacy. This study was aimed to evaluate the efficacy of medications, based on NeP phenotypes, and to propose symptom-based pharmacotherapy. This retrospective study was enrolled 265 outpatients with chronic NeP related to spinal disorders. The patients were classified into three groups: spinal cord-related pain, radicular pain, and cauda equina syndrome. Data were obtained from patient-based questionnaires using Neuropathic Pain Symptom Inventory (NPSI) and the Brief Scale for Psychiatric Problems in Orthopaedic Patients, and from clinical information. The proportions of patients with ≥ 30% and ≥ 50% reduction in NPSI score for each pain subtype (spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia) and drugs were evaluated. The pain reduction rate was significantly lower in patients with spinal cord-related pain, especially for paresthesia/dysesthesia. For spinal cord-related pain, duloxetine and neurotropin had insufficient analgesic effects, whereas mirogabalin was the most effective. Pregabalin or mirogabalin for radicular pain and duloxetine for cauda equina syndrome are recommended in cases of insufficient analgesic effects with neurotropin. The findings could contribute to better strategies for symptom-based pharmacotherapeutic management.

show abstract

Effects of duloxetine on pain and walking distance in neuropathic pain models via modulation of the spinal monoamine system

Cited by 13 publications

References 62 publications

Identification of key candidate genes in neuropathic pain by integrated bioinformatic analysis

Identification of key candidate genes in neuropathic pain by integrated bioinformatic analysis

Reduction in anxiety during treatment with exercise and duloxetine is related to improvement of low back pain-related disability in patients with non-specific chronic low back pain

Symptom-based pharmacotherapy for neuropathic pain related to spinal disorders: results from a patient-based assessment

Contact Info

Product

Resources

About